Hot Features
Premium
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Nabriva Therapeutics PLC | NBRV | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 1.42 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 1.42 | 1.42 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 1.35 - 2.24 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 1.42 | USD |
Nabriva Therapeutics PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 0 | 0.00 | - | 37.51M | -57.19M | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Nabriva Therapeutics News
| Date | Time | Source | News Article |
|---|---|---|---|
| 10/25/2023 | 12:43 | Edgar (US Regulatory) | Form 15-12G - Securities registration termination [Section.. |
| 10/24/2023 | 23:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness |
| 10/19/2023 | 20:01 | Edgar (US Regulatory) | Form POS AM - Post-Effective amendments for registration.. |
| 10/19/2023 | 19:22 | Edgar (US Regulatory) | Form S-8 POS - Securities to be offered to employees in.. |
| 7/31/2023 | 07:07 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/24/2023 | 08:00 | Edgar (US Regulatory) | Form 8-K - Current report |
| 7/10/2023 | 15:01 | GlobeNewswire Inc. | Arbutus Appoints Two New Executives |
| 7/07/2023 | 15:34 | Edgar (US Regulatory) | Form 8-K - Current report |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical NBRV Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Month | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6 Months | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1 Year | 1.5201 | 2.24 | 1.35 | 1.55 | 25,475 | -0.1001 | -6.59% |
| 3 Years | 1.74 | 5.75 | 0.1516 | 0.9461038 | 993,228 | -0.32 | -18.39% |
| 5 Years | 21.80 | 28.09 | 0.1516 | 6.44 | 1,701,614 | -20.38 | -93.49% |
Nabriva Therapeutics Description
| Nabriva Therapeutics PLC is a clinical stage biopharmaceutical company. Nabriva is engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The company is developing product candidate, lefamulin, to be the first pleuromutilin antibiotic available for systemic administration in humans. It operates in one reportable segment, which comprises the research and development of novel anti-infective agents to treat serious infections. |
